Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Glioma | Research

Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma

Authors: Enfang Shan, Yi-nan Cao, Yang Zhang, Wen Chen, Xurui Ren, Shanjie Zhu, Xueru Xi, Shuai Mu, Mian Ma, Tongle Zhi, Xianwen Li

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Gliomas are the most common malignant primary brain tumors in adults with poor prognoses. The purpose of this study is to explore CACNG3 as a prognostic factor that is closely related to the progression and survival outcome of gliomas and to provide a potential new molecular target for the diagnosis and treatment of glioma patients. CACNG3 expression and related clinical data were collected from three major databases of The Chinese Glioma Genome Atlas (CGGA), The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO). The CGGA dataset was used as a training set, and TCGA and GEO datasets obtained from the GEO database were used for validation. CACNG3 was expressed at low levels in the tumor group, and the overall survival (OS) in patients with low CACNG3 expression is shorter. Furthermore, CACNG3 expression was negatively associated with glioma grades, which was confirmed in the IHC results of clinical samples. The expression level of CACNG3 in the IDH1 wide-type group, 1p/19q non-codel group, and mesenchymal subtype group was significantly reduced, and the results showed that CACNG3 could serve as a biomarker for the mesenchymal molecular subtype. In addition, the univariate and multivariate analysis verified the prognostic value of CACNG3 in predicting the OS of gliomas of all grades. The results of functional annotation and pathway enrichment analysis of differently expressed genes(DEGs), showed that CACNG3 might affect the development of glioma by interfering with synaptic transmission. Moreover, temozolomide (TMZ), commonly used in the treatment of glioma, increased CACNG3 expression in a dose and time-dependent manner. Therefore, CACNG3 plays a vital role in the occurrence and development of gliomas and can serve as a potential biomarker for targeted therapy and further investigation in the future.
Appendix
Available only for authorised users
Literature
1.
Ostrom QT et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neurooncology, 2017. 19(suppl_5).
2.
Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet (London England). 2018;392(10145):432–46.CrossRefPubMed
3.
4.
Jiang T, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021;499:60–72.CrossRefPubMed
5.
Molinaro AM, et al. Genetic and molecular epidemiology of adult diffuse glioma. Nat Reviews Neurol. 2019;15(7):405–17.CrossRef
6.
7.
Black JL. The voltage-gated calcium channel gamma subunits: a review of the literature. J Bioenerg Biomembr. 2003;35(6):649–60.CrossRefPubMed
8.
Amenta F, et al. Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci. 2009;283(1–2):219–23.CrossRefPubMed
9.
10.
Ortner NJ, Striessnig J. L-type calcium channels as drug targets in CNS disorders Channels (Austin, Tex.), 2016. 10(1).
11.
Klugbauer N, et al. A family of gamma-like calcium channel subunits. FEBS Lett. 2000;470(2):189–97.CrossRefPubMed
12.
Sharp AH, et al. Biochemical and anatomical evidence for specialized voltage-dependent calcium channel gamma isoform expression in the epileptic and ataxic mouse, stargazer. Neuroscience. 2001;105(3):599–617.CrossRefPubMed
13.
Everett KV, et al. Linkage and association analysis of CACNG3 in childhood absence epilepsy. Eur J Hum Genetics: EJHG. 2007;15(4):463–72.CrossRefPubMed
14.
15.
16.
Kanehisa M, Furumichi M, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.CrossRefPubMed
17.
Siegal T. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.Advances and Technical Standards In Neurosurgery, 2016(43).
18.
Shen T, et al. Exogenous growth factors enhance the expression of cola1, cola3, and Elastin in fibroblasts via activating MAPK signaling pathway. Mol Cell Biochem. 2018;442(1–2):203–10.CrossRefPubMed
19.
Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277(2):301–8.CrossRefPubMed
20.
Liu Y, et al. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer. Tumour Biology: the Journal of the International Society For Oncodevelopmental Biology and Medicine. 2015;36(6):4377–86.CrossRefPubMed
21.
Lin L, Cai J, Jiang C. Recent advances in targeted therapy for Glioma. Curr Med Chem. 2017;24(13):1365–81.CrossRefPubMed
22.
Reuss DE, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–73.CrossRefPubMedPubMedCentral
23.
24.
25.
Malarkey EB, Parpura V. Mechanisms of glutamate release from astrocytes. Neurochem Int. 2008;52(1–2):142–54.CrossRefPubMed
26.
Leanza L et al. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. Biochim Biophys Acta, 2016. 1863(6 Pt B): p. 1385–97.
27.
28.
Zhao W, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit. Cancer Cell. 2013;23(4):541–56.CrossRefPubMed
29.
Zhang Y, et al. Inhibition of T-type Ca2+ channels by endostatin attenuates human glioblastoma cell proliferation and migration. Br J Pharmacol. 2012;166(4):1247–60.CrossRefPubMedPubMedCentral
30.
Rapôso C, et al. Effect of Phoneutria nigriventer venom on the expression of junctional protein and P-gp efflux pump function in the blood-brain barrier. Neurochem Res. 2012;37(9):1967–81.CrossRefPubMed
31.
Parpura V, Grubišić V, Verkhratsky A. Ca(2+) sources for the exocytotic release of glutamate from astrocytes. Biochim Biophys Acta. 2011;1813(5):984–91.CrossRefPubMed
32.
33.
34.
Tomita S, Nicoll RA, Bredt DS. PDZ protein interactions regulating glutamate receptor function and plasticity. J Cell Biol. 2001;153(5):F19–F24.CrossRefPubMed
35.
Okada Y. Ion channels and transporters involved in cell volume regulation and sensor mechanisms. Cell Biochem Biophys. 2004;41(2):233–58.CrossRefPubMed
36.
Sugano K, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov. 2010;9(8):597–614.CrossRefPubMed
37.
Hudmon A, et al. CaMKII tethers to L-type Ca2 + channels, establishing a local and dedicated integrator of Ca2 + signals for facilitation. J Cell Biol. 2005;171(3):537–47.CrossRefPubMedPubMedCentral
38.
Strack S, McNeill RB, Colbran RJ. Mechanism and regulation of calcium/calmodulin-dependent protein kinase II targeting to the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 2000;275(31):23798–806.CrossRefPubMed
39.
Coultrap SJ, et al. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014;6(3):431–7.CrossRefPubMedPubMedCentral
40.
Chapman ER, et al. SNAP-25, a t-SNARE which binds to both syntaxin and synaptobrevin via domains that may form coiled coils. J Biol Chem. 1994;269(44):27427–32.CrossRefPubMed
41.
42.
Sharma M, et al. CSPα knockout causes neurodegeneration by impairing SNAP-25 function. EMBO J. 2012;31(4):829–41.CrossRefPubMed
Metadata
Title
Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma
Authors
Enfang Shan
Yi-nan Cao
Yang Zhang
Wen Chen
Xurui Ren
Shanjie Zhu
Xueru Xi
Shuai Mu
Mian Ma
Tongle Zhi
Xianwen Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10896-1

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma

Research

Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence

Research

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Research

One year overall survival of wilms tumor cases and its predictors, among children diagnosed at a teaching hospital in South Western Uganda: a retrospective cohort study

Research

Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma

Research

Regulation of HHLA2 expression in kidney cancer and myeloid cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits